Get started
TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDATENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDATENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA

TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RMDA chart


Full chart

Key stats


Market capitalization
‪6.66 B‬ EGP
Dividend yield (indicated)
1.52%
Price to earnings Ratio (TTM)
26.358
Basic EPS (TTM)
0.163 EGP
Net income (FY)
‪223.50 M‬ EGP
Revenue (FY)
‪1.92 B‬ EGP
Shares float
‪998.82 M‬
Beta (1Y)
0.86

About TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Amr Morsy
Website
ramedapharma.com
Headquarters
6th of October City
Founded
1986
ISIN
EGS381B1C015
FIGI
BBG00QYLW137
Tenth of Ramadan Company for Pharmaceuticals Industries & Diagnostic Reagents S.A.E. engages in the manufacture and marketing of pharmaceutical products for human and veterinary use. It operates through Production and Selling of Pharmaceutical Products; and Manufacturing for Others segments. The firm product categories include anti-infective, anti-diabetic, respiratory, ophthalmology, gastro-intestinal tract, cardio-vascular, central nervous system, vitamins, and analgesics. The company was founded on January 15, 1986 and is headquartered in 6th of October City, Egypt.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RMDA news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as RMDA.

Frequently Asked Questions


The current price of RMDA is 4.400 EGP — it has increased by 3.04% in the past 24 hours. Watch TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EGX exchange TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stocks are traded under the ticker RMDA.
RMDA stock has fallen by −0.45% compared to the previous week, the month change is a 17.33% rise, over the last year TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA has showed a 57.14% increase.
We've gathered analysts' opinions on TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA future price: according to them, RMDA price has a max estimate of 6.50 EGP and a min estimate of 4.50 EGP. Watch RMDA chart and read a more detailed TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stock forecast: see what analysts think of TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA and suggest that you do with its stocks.
RMDA reached its all-time high on Mar 13, 2025 with the price of 4.670 EGP, and its all-time low was 0.126 EGP and was reached on Nov 27, 2019. View more price dynamics on RMDA chart.
See other stocks reaching their highest and lowest prices.
RMDA stock is 7.73% volatile and has beta coefficient of 0.86. Track TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stock price on the chart and check out the list of the most volatile stocks — is TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA there?
Today TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA has the market capitalization of ‪6.66 B‬, it has increased by 3.56% over the last week.
Yes, you can track TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA financials in yearly and quarterly reports right on TradingView.
RMDA net income for the last quarter is ‪61.84 M‬ EGP, while the quarter before that showed ‪57.01 M‬ EGP of net income which accounts for 8.47% change. Track more TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA financial stats to get the full picture.
TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA dividend yield was 3.93% in 2023, and payout ratio reached 44.76%. The year before the numbers were 0.00% and 0.00% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA EBITDA is ‪547.01 M‬ EGP, and current EBITDA margin is 26.02%. See more stats in TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA financial statements.
Like other stocks, RMDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA stock shows the buy signal. See more of TENTH OF RAMADAN PHARMACEUTICAL INDUSTRIES&DIAGNOSTIC-RAMEDA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.